Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
Joseph Heskin, Scott J C Pallett, Nabeela Mughal, Gary W Davies, Luke S P Moore, Michael Rayment, Rachael Jones
Topics & Concepts
RitonavirProtease inhibitor (pharmacology)CobicistatMedicinePillDrugPharmacologyHuman immunodeficiency virus (HIV)Government (linguistics)Intensive care medicineGeneral partnershipLopinavirClinical trialPharmaceutical industryAntiretroviral therapyHealth servicesAdverse effectExpanded accessCYP3A4LentivirusHIV/AIDS drug development and treatmentPharmacogenetics and Drug MetabolismHIV-related health complications and treatments